The tumor microbiota—which includes bacteria, fungi, viruses, and other microorganisms present in tumor tissue—is now considered an important component of the tumor microenvironment. An international consensus article published in Cancer Cell brings together institutions from the United States, Israel, Austria, and Italy, engaged in cutting-edge studies in this specific research area.

A new daily pill to help with weight loss has been approved by the U.S. Food and Drug Administration (FDA), and it moved through review faster than most drugs in recent years.

A team of scientists led by the National Cancer Center Singapore (NCCS) and Duke-NUS Medical School (Duke-NUS) has found a new approach for treating some of the world's most aggressive cancers associated with BAP1 mutations. Their research, published in the journal Science Translational Medicine on 1 April 2026, uncovers how BAP1 functions at the molecular level and presents a novel therapeutic strategy to slow the progression of mesothelioma, uveal melanoma, cholangiocarcinoma, and clear cell renal cell carcinoma harboring BAP1 mutations.

Folks with severe plaque psoriasis often have to choose between convenient pills that don't work very well or highly effective injections that come with the hassle of needles. That trade-off may soon change. New clinical trial data suggests a once-daily pill called zasocitinib may provide the clear skin once only expected from shots.

Neuroscientists at University of Iowa Health Care have demonstrated for the first time that noninvasive brain stimulation can alter the activity of a critical deep brain region involved in emotion and memory. Moreover, the study shows that personalizing the stimulation site using a patient's unique brain connectivity pathway can increase the neuromodulation effect.

New findings from VCU Massey Comprehensive Cancer Center and the VCU Institute of Molecular Medicine (VIMM), published in Pharmacological Research, show that an innovative drug effectively prevents prostate tumors from spreading to an advanced and incurable stage in the bones. The targeted small molecule inhibitor, IVMT-Rx-4, also enhances standard-of-care chemotherapy treatment for the disease, offering significant potential for a paradigm shift in the treatment of metastatic tumors.

A new study shows that migration from Mexico to the United States can influence cardiovascular risk profiles. The study's findings are important for clinicians who serve immigrant populations and who would need to consider how time in the U.S. can lead to changes in lifestyle factors, including diet and physical activity that can influence health.

A new study from the Peter Doherty Institute for Infection and Immunity shows that seasonal influenza vaccination does more than protect against viruses circulating that year; it can also prime the immune system to respond to future strains, including some that emerge decades later. Researchers analyzed blood samples collected in 1994 from adults that had been recently vaccinated against influenza to track how their immune responses fared against influenza strains that circulated over the next 30 years, including influenza A (H1N1, H3N2) and influenza B.

Alain Chariot's team has just published a study in EMBO Molecular Medicine shedding light on the unexpected role of the Stard7 protein in the development of intestinal cancers. Long regarded as a simple lipid transporter, Stard7 now emerges as a key player in mitochondrial metabolism and tumor initiation in the intestine.

Researchers from the Biomedical Data Science Laboratory (BDSLab) at the ITACA Institute of the Universitat Politècnica de València have developed a new method based on magnetic resonance imaging that enables objective quantification of the growth of the most aggressive brain tumors, particularly glioblastoma. The study, published in the journal Medical Physics, addresses one of the main clinical challenges in the diagnosis and treatment of this tumor: its high capacity to infiltrate healthy brain tissue.